Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson’s
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53070#.VLST3cnQrzE Author(s) Ulises Rodríguez Ortiz 1 , Daniel San- Juan 1 , Francesco Scarci 2* Affiliation(s) 1 Movement Disorders Clinic and Neurophysiology Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico . 2 Scientific Department, Polichem S.A., Lugano, Switzerland . ABSTRACT A randomized, double blind, and active reference-controlled study was carried out among 116 patients suffering from idiopathic Parkinson’s disease (PD). The aim of the study was to compare the safety and efficacy of alpha-dihydroergocryptine (DHEC) vs. pramipexole (PRAM) as an adjunct symptomatic therapy to levodopa in PD patients. The motor symptoms, assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) III subscale, was identified as efficacy target. Fifty-six patients were randomized to DHEC and 60 to PRAM. Patients included were...